Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study

Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population‐based cohort study

(2019) Kristian B. Filion et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care

(2019) Elisabetta Patorno et al.   CIRCULATION

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

(2019) Shih-Chieh Shao et al.   Cardiovascular Diabetology

Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study

(2019) Björn Pasternak et al.   BMJ-British Medical Journal

A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes

(2019) Michael E. Nassif et al.   AMERICAN JOURNAL OF CARDIOLOGY

Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus

(2018) Rinkoo Dalan   Cardiology in Review

Reduced Mortality With Sodium-Glucose Cotransporter–2 Inhibitors in Observational Studies

(2018) Samy Suissa   CIRCULATION

DECLARE-TIMI 58: Participants’ baseline characteristics

(2018) Itamar Raz et al.   DIABETES OBESITY & METABOLISM

SGLT-2 Inhibitors and Cardiovascular Risk

(2018) Matthew A. Cavender et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

(2018) Elisabetta Patorno et al.   BMJ-British Medical Journal

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

(2018) Elisabetta Patorno et al.   BMJ-British Medical Journal

Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes

(2018) Ghadeer K. Dawwas et al.   DIABETES OBESITY & METABOLISM

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

(2018) Julio Rosenstock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

(2018) Peter Ueda et al.   BMJ-British Medical Journal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors

(2017) Matthew H. Secrest et al.   TRENDS IN CARDIOVASCULAR MEDICINE

Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor

(2017) Jacob A. Udell et al.   CIRCULATION

DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty

(2016) Kristian B. Filion et al.   DIABETES CARE

Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores

(2016) Samy Suissa et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Data Resource Profile: Clinical Practice Research Datalink (CPRD)

(2015) Emily Herrett et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metformin and the Risk of Cancer: Time-related biases in observational studies

(2012) S. Suissa et al.   DIABETES CARE

Substituting placebo for established, effective therapy: Why not?

(2010) S. Shapiro et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Variations Between Clinical Trial Participants and Medicare Beneficiaries in Evidence Used for Medicare National Coverage Decisions

(2008) Sanket S. Dhruva   ARCHIVES OF INTERNAL MEDICINE